PARIS, May 4, 2023 — CGG, a global leader in technology and HPC, uses artificial intelligence (AI) to increase speed, cost, novelty and success in new drug development.
CGG provides Biosimulytics with fully customized HPC (High Performance Computing), AI and cloud solutions. Using CGG’s algorithms and HPC expertise, Biosimulytics will be able to fully extend its groundbreaking Pharmatech platform, which provides powerful predictive simulation capabilities to pharmaceutical companies worldwide when developing new drug molecules. increase. Their innovative approach accelerates time to market, de-risks critical developments in the transition from Molecular to Medical (M2M) in the pharmaceutical industry, and is a key technology enabling a new era of precision medicine. is.
CGG’s custom solutions meet the needs of Biosimulytics professionals for high-performance HPC and AI environments, optimizing a suite of specialized molecular simulation applications from crystal structure prediction (CSP) to structure-based drug discovery (SBDD). increase. Biosimulytics can now run applications at least five times faster than their previous public cloud solution, dramatically improving their return on investment and enabling them to grow their business. As a European company providing cloud services hosted in the European Union, CGG also provides full EU regulation legal protection for the intellectual property of his Biosimulytics and its customers.
Headquartered in NovaUCD, Dublin, Biosimulytics is a University College Dublin (UCD) spin-out company with strong national and European backing and a digital R&D solutions provider to some of the world’s leading pharmaceutical companies. I am working as
Biosimulytics CEO Peter Doyle said: The AI drug development space is currently at an inflection point and the market is expected to exceed US$10 billion by 2030, growing at his CAGR of 25%. Our goal is to make AI-powered predictive technology more accessible, affordable and widely used by everyone, from large pharmaceutical companies to small biotech start-ups, leading the global pharmaceutical industry. to develop potential molecules into approved drugs faster and with a much higher chance of success. His announcement at CGG today is an important milestone in that journey. ”
Agnès Boudot, EVP of HPC & Cloud Solutions at CGG, said: After successfully establishing cloud service offerings in the energy, energy transition and mining sectors, where more than 30 external clients now directly access and use CGG cloud solution services to provide insight into their data, We are excited to expand into healthcare and living. We support Biosimulytics with AI and HPC-based technologies to help develop new and improved therapeutics faster and more cost-effectively. Her experience in hosting and optimizing scientific workflows running at over 350 petaflops at industrial scale ensures that she can provide Biosimulytics with scalable solutions that meet the future growth requirements of this complex HPC and AI workflow. ”
About CGG
CGG (www.cgg.com) is a global technology and HPC leader providing data, products, services and solutions in the fields of geosciences, data science, sensing and monitoring. Our unique portfolio supports clients in efficiently and responsibly solving complex digital, energy transition, natural resource, environmental and infrastructure challenges towards a more sustainable future. CGG has approximately 3,400 employees worldwide and is listed on Euronext Paris SA (ISIN: 0013181864).
Source: CGG
